Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Non-small Cell Carcinoma × osimertinib × 1 year × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 71 Lung Neoplasms 27 Neoplasms 6 Neoplasm Metastasis 5 Carcinoma 4 NSCLC 3 Colorectal Neoplasms 3 Non Small Cell Lung Cancer Metastatic 2 Meningeal Carcinomatosis 2 Head and Neck Neoplasms 2 Brain Neoplasms 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Stage II-IIIB Non-small Cell Lung Carcinoma 1 Stage IB-IIIA Non-small Cell Lung Carcinoma 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Resectable Non-small Cell Lung Cancer 1 Recurrence 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Non-small Cell Carcinoma 1 Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder) 1 NSCLC Patients With Brain Metastasis 1 Multiple Myeloma 1 Mesothelioma 1 Lymphoma 1 Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC) 1

Interventions

pembrolizumab 1 osimertinib 1 binimetinib 1 Pemetrexed 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04695925 2025-10-15

TOP

Sun Yat-sen University

Phase 3 Active not recruiting

Non-small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡